Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2B3-101 in patients with breast cancer leptomeningeal metastases
2012-005096-13Phase 2Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2012
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin glutathione pegylated liposomal in Carcinomatous Meningitis (CM) and breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Tumor response by LM response score. Started Nov 2012; status: terminated.
02
Drugs
doxorubicin glutathione pegylated liposomal
03
Conditions
Carcinomatous Meningitis (CM)breast cancer
Beyond the preview
Go deeper on 2012-005096-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005096-13.